Minnesota SF 1806: Sartell Sauk River regional park grant purpose modification

Status: Referred to Capital Investment (as of 2017-03-06)

State: Minnesota · Session: 2017-2018 · Bill: SF 1806

Subjects: Cities and Towns-Specific, Parks and Trails

Sponsors: Fischbach

Bill Text

1.1 A bill for an act
1.2 relating to health; prohibiting certain formulary changes during the plan year;
1.3 prohibiting the medical assistance program from implementing changes to its
1.4 formulary for certain enrollees; amending Minnesota Statutes 2024, section
1.5 256B.0625, subdivision 13; proposing coding for new law in Minnesota Statutes,
1.6 chapter 62Q.
1.7 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:
1.8 Section 1. [62Q.83] FORMULARY CHANGES.
1.9 Subdivision 1.Definitions.(a) For purposes of this section, the following terms have
1.10 the meanings given.
1.11 (b) "Drug" has the meaning given in section 151.01, subdivision 5.
1.12 (c) "Enrollee" has the meaning given in section 62Q.01, subdivision 2b.
1.13 (d) "Formulary" means a current list of covered prescription drug products that is subject
1.14 to periodic review and update.
1.15 (e) "Health plan" has the meaning given in section 62Q.01, subdivision 3.
1.16 (f) "Pharmacy benefit manager" has the meaning given in section 62W.02, subdivision
1.17 15.
1.18 (g) "Prescription" has the meaning given in section 151.01, subdivision 16a.
1.19 Subd. 2.Formulary changes.(a) Except as provided in paragraphs (b) and (c), a health
1.20 plan must not, with respect to an enrollee who was previously prescribed the drug during
1.21 the plan year, remove a drug from the health plan's formulary or place a drug in a benefit
1.22 category that increases the enrollee's cost for the duration of the enrollee's plan year.
1Section 1.
S1806-1 1st EngrossmentSF1806 REVISOR RSI
SENATE
STATE OF MINNESOTA
S.F. No. 1806NINETY-FOURTH SESSION
(SENATE AUTHORS: MANN, Wiklund, Lieske, Gruenhagen and Pha)
OFFICIAL STATUSD-PGDATE
Introduction and first reading48202/24/2025
Referred to Commerce and Consumer Protection
Comm report: To pass as amended and re-refer to Health and Human Services735a03/13/2025
Author added Pha776
See First Special Session, HF2

2.1 (b) Paragraph (a) does not apply if a health plan changes the health plan's formulary:
2.2 (1) for a drug that has been deemed unsafe by the United States Food and Drug
2.3 Administration (FDA);
2.4 (2) for a drug that has been withdrawn by the FDA or the drug manufacturer; or
2.5 (3) when an independent source of research, clinical guidelines, or evidence-based
2.6 standards has issued drug-specific warnings or recommended changes with respect to a
2.7 drug's use for reasons related to previously unknown and imminent patient harm.
2.8 (c) Paragraph (a) does not apply if a health plan removes a brand name drug from the
2.9 health plan's formulary or places a brand name drug in a benefit category that increases the
2.10 enrollee's cost if the health plan:
2.11 (1) adds to the health plan's formulary a generic or multisource brand name drug rated
2.12 as therapeutically equivalent according to the FDA Orange Book, or a biologic drug rated
2.13 as interchangeable according to the FDA Purple Book, at a lower cost to the enrollee; and
2.14 (2) provides at least a 60-day notice to prescribers, pharmacists, and affected enrollees.
2.15 EFFECTIVE DATE.This section is effective January 1, 2026, and applies to health
2.16 plans offered, sold, issued, or renewed on or after that date.
2.17 Sec. 2. Minnesota Statutes 2024, section 256B.0625, subdivision 13, is amended to read:
2.18 Subd. 13.Drugs.(a) Medical assistance covers drugs, except for fertility drugs when
2.19 specifically used to enhance fertility, if prescribed by a licensed practitioner and dispensed
2.20 by a licensed pharmacist, by a physician enrolled in the medical assistance program as a
2.21 dispensing physician, or by a physician, a physician assistant, or an advanced practice
2.22 registered nurse employed by or under contract with a community health board as defined
2.23 in section 145A.02, subdivision 5, for the purposes of communicable disease control.
2.24 (b) The dispensed quantity of a prescription drug must not exceed a 34-day supply unless
2.25 authorized by the commissioner or as provided in paragraph (h) or the drug appears on the
2.26 90-day supply list published by the commissioner. The 90-day supply list shall be published
2.27 by the commissioner on the department's website. The commissioner may add to, delete
2.28 from, and otherwise modify the 90-day supply list after providing public notice and the
2.29 opportunity for a 15-day public comment period. The 90-day supply list may include
2.30 cost-effective generic drugs and shall not include controlled substances.
2.31 (c) For the purpose of this subdivision and subdivision 13d, an "active pharmaceutical
2.32 ingredient" is defined as a substance that is represented for use in a drug and when used in
2Sec. 2.
S1806-1 1st EngrossmentSF1806 REVISOR RSI

3.1 the manufacturing, processing, or packaging of a drug becomes an active ingredient of the
3.2 drug product. An "excipient" is defined as an inert substance u

View Minnesota SF 1806 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.